{"status": "OK", "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved.", "response": {"docs": [{"word_count": "1718", "slideshow_credits": null, "multimedia": [{"type": "image", "subtype": "wide", "width": 190, "height": 126, "url": "images/2006/07/18/business/0718-biz-PFIZER-for-web.126.jpg", "legacy": {"wideheight": "126", "widewidth": "190", "wide": "images/2006/07/18/business/0718-biz-PFIZER-for-web.126.jpg"}}, {"type": "image", "subtype": "xlarge", "width": 600, "height": 280, "url": "images/2006/07/18/business/18pfizer.xlarge.jpg", "legacy": {"xlarge": "images/2006/07/18/business/18pfizer.xlarge.jpg", "xlargeheight": "280", "xlargewidth": "600"}}, {"type": "image", "subtype": "thumbnail", "width": 75, "height": 75, "url": "images/2006/07/18/business/18pfizer.751.jpg", "legacy": {"thumbnail": "images/2006/07/18/business/18pfizer.751.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}}], "news_desk": "Business", "pub_date": "2006-07-18T00:00:00Z", "source": "The New York Times", "web_url": "http://www.nytimes.com/2006/07/18/business/18pfizer.html", "blog": [], "_id": "54ae8b2f7988105cf60961b9", "headline": {"sub": "A Pfizer Scientist Sees Research Dividends Ahead ;", "print_headline": "Dr. Optimistic", "main": "A Pfizer Scientist Sees Research Dividends Ahead"}, "subsection_name": null, "abstract": null, "section_name": "Business Day", "byline": {"original": "By ALEX BERENSON", "person": [{"rank": 1, "firstname": "Alex", "lastname": "BERENSON", "role": "reported", "organization": ""}]}, "print_page": "1", "document_type": "article", "type_of_material": "News", "keywords": [{"rank": "1", "value": "Pfizer Inc", "name": "organizations", "is_major": "N"}, {"rank": "2", "value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "N"}, {"rank": "3", "value": "Cholesterol", "name": "subject", "is_major": "N"}, {"rank": "4", "value": "Medicine and Health", "name": "subject", "is_major": "N"}], "lead_paragraph": "In a business where failure is the norm, Dr. John L. LaMattina, the top scientist for Pfizer, counts himself as an incurable optimist.", "snippet": "In a business where failure is the norm, Dr. John L. LaMattina, the top scientist for Pfizer, counts himself as an incurable optimist."}], "meta": {"offset": 0, "hits": 1, "time": 32}}}